Herantis Pharma releases update on timeline of its ongoing CDNF trial
Category: #health  | By Nikita Chaurasia  | Date: 2019-09-30 |
  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn

Herantis Pharma releases update on timeline of its ongoing CDNF trial

Parkinson's disease (PD) is an incurable, progressive neurodegenerative disease which is caused by the death of dopaminergic neurons in the midbrain. With medication, motor symptoms can be treated but it is impossible to prevent the progression of this disease. Currently, numerous clinical trials are being carried out across the world to develop new treatments to slow down the progression of this disease in an efficient way.

Herantis Pharma Plc has reportedly released a new update regarding the timeline for its ongoing Phase 1-2 trial that examines its new drug candidate, CDNF, and neuroprotective factor, in patients who are suffering from Parkinson’s disease. 

According to the sources, the patient recruitment procedure has been completed. 17 patients have been implanted with a medical device which will be used for injecting CDNF. 

Sources cite that the trial will proceed further as per the scheduled timeline as is expected to finish patient visits by the last quarter (Q4) of 2019. The analysis and completion of the data for the study’s unblinding might be completed by the end of the first quarter (Q1) of 2020. Thus, Herantis is updating guidance on the topline data announcement of study from Q4 of this year to the Q1 of next year.

The main objective of this study is to evaluate the tolerability and safety of CDNF and the drug delivery device’s dosing efficiency. After completing the main study, the patients may continue with CDNF doses for another six months. The extension study would be followed by a follow-up study.

Pekka Simula, CEO of Herantis stated that the company’s first-in-human CDNF study is carried out in patients who are suffering from advanced Parkinson’s disease. Assessment of the safety criteria will depend on complete analysis. Moreover, it is vital to take enough time to interpret and prepare the trial results before proceeding with the unblinding of the study. 

The information regarding tolerability and safety will equip the company with fundamental details that are required to determine the future road map of this treatment.

Source Credit - http://herantis.com/release/herantis-pharma-plc-provides-update-on-timeline-for-ongoing-phase-1-2-cdnf-trial/#

  • shareshare_icon
  • Twitter
  • Facebook
  • LinkedIn


About Author

Nikita Chaurasia     twitter

Nikita Chaurasia

Having always been daft at wordplay, Nikita Chaurasia, post the completion of post-graduation, commenced her journey into the content generation cosmos. Endowed with a professional MBA degree in Advertising and Public Relations, Nikita strives to integrate her creativ...

Read More..

More News By Nikita Chaurasia

General Motors passes Ford to become the second-best EV seller in U.S.

General Motors passes Ford to become the second-best EV seller in U.S.

By Nikita Chaurasia

Detroit-based American multinational automaker, General Motors, has reportedly pulled ahead of fellow American rival, Ford Motor, to establish itself as second-biggest seller of all-electric vehicles in the US during the first quarter of 2023. The...

McKinsey commences job cuts focused on non-client serving teams

McKinsey commences job cuts focused on non-client serving teams

By Nikita Chaurasia

McKinsey and Co. a consulting giant entity has decided to start cutting jobs in one of the biggest rounds of layoffs for the company. This is likely to eliminate the jobs of about 2000 employees from work. The layoffs will be focused on support st...

Fintech firm PayPal to shed around 2000 staff as global economy plummets

Fintech firm PayPal to shed around 2000 staff as global economy plummets

By Nikita Chaurasia

PayPal, the U.S.-based fintech giant, has reportedly announced that it will cut nearly 2000 jobs, approximately 7% of its workforce, as it turns the latest prominent tech company to shed staff in a bid to cut costs. The online payments provider cl...